IDiyas

For the Inventor, By the Inventor

Libertyville, IL, United States of America

Clint D Brooks

USPTO Granted Patents = 15

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 60(Granted Patents)


Company Filing History:

goldMedal15 out of 4,177 
 
Abbott Laboratories Corporation
 patents

Years Active: 1995-1999

Loading Chart...
15 patents (USPTO):Explore Patents
1. 5863946 - Iminoxyderivatives of fenamates as inhibitors of prostaglandin (1999-01-26),
2. 5843968 - Symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates as inhibitors (1998-12-01),
3. 5840758 - Oxime derivatives of fenamates as inhibitors of prostaglandin (1998-11-24),
4. 5795900 - Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as (1998-08-18),
5. 5783586 - Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of (1998-07-21),
6. 5756531 - Iminoxy derivatives of indole and indene compounds as inhibitors of (1998-05-26),
7. 5750558 - Oxime derivatives of indole and indene compounds as inhibitors of (1998-05-12),
8. 5714488 - Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of (1998-02-03),
9. 5691351 - Bis-(Heteroarylmethoxyphenyl)cycloalkyl carboxylates as inhibitors of (1997-11-25),
10. 5668150 - Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as (1997-09-16),
11. 5668146 - Symmetrical bis-heteroarylmethoxyphenyliminoxyalkyl carboxylates as (1997-09-16),
12. 5616596 - Substituted arylalkynyl-and heteroarylalkynl-N-hydroxyurea inhibitors of (1997-04-01),
13. 5516789 - Lipoxygenase and cyclooxygenase inhibiting compounds (1996-05-14),
14. 5446055 - Polyether naphthalenic lignan lactones as inhibitors of 5-lipoxygenase (1995-08-29),
15. 5426111 - [Alkoxy-, alkenyloxy-, alkynyloxy-, and phenylmethyloxyalkoxycycloalkyl (1995-06-20),

Title: **Clint D Brooks: Innovator in Pharmaceutical Science**

Introduction

Clint D Brooks, based in Libertyville, IL, has made significant contributions to the field of pharmaceutical innovations through his extensive work as an inventor. With an impressive portfolio of 15 patents, his research has paved the way for advancements in treating inflammatory diseases and allergic conditions.

Latest Patents

Brooks's latest patent focuses on Iminoxyderivatives of fenamates, which act as inhibitors of prostaglandin biosynthesis. These compounds, defined by specific molecular formulas and structures, have the potential to impact treatments for various inflammatory diseases by effectively inhibiting prostaglandin production. Another notable patent is centered around symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates, which also serve as inhibitors, specifically targeting leukotriene biosynthesis. These innovations contribute significantly to therapeutic strategies aimed at managing allergic and inflammatory disease states through composition formulations and methods of action.

Career Highlights

Clint D Brooks currently works at Abbott Laboratories Corporation, a renowned global healthcare company that has been pivotal in advancing health and wellness through science. His role encompasses extensive research and development, contributing to groundbreaking solutions in pharmaceuticals that improve patient outcomes.

Collaborations

Throughout his career, Brooks has had the opportunity to collaborate with esteemed coworkers, including Teodozyj Kolasa and Andrew O Stewart. These collaborations further enhance the innovative efforts at Abbott Laboratories, combining expertise to drive forward therapeutic advancements in the healthcare sector.

Conclusion

Clint D Brooks exemplifies the impact an inventor can have within the pharmaceutical industry. His contributions are not only reflected in his numerous patents but also in the potential health benefits for patients suffering from inflammatory diseases. As he continues to innovate within Abbott Laboratories Corporation, his work remains crucial to the evolution of medical treatments and advancements in public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…